Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery- Åsberg Depression Rating Scale and the 9-item Patient Health Questionnaire

CONCLUSIONS: In adults with TRD, ESK + OAD significantly improved severity of depressive symptoms, and more patients achieved clinically meaningful changes in depressive symptoms based on PHQ-9, versus OAD + PBO. PHQ-9 outcomes were consistent with those of clinician-rated MADRS.TRIAL REGISTRATION: ClinicalTrials.gov: NCT02417064, NCT02418585, NCT02493868.PMID:38557430 | DOI:10.1017/S1092852924000105

Source: CNS Spectrums - April 1, 2024 Category: Neurology Authors: Jennifer Kern Sliwa Ronaldo R Naranjo Ibrahim Turkoz Mary Pat Petrillo Patricia Cabrera Madhukar Trivedi Source Type: research